MAAT Share Price Performance
€6.90
-0.42 (-5.74%)
Price €6.90
Share Pricen/a
MaaT Pharma SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
MAAT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
MaaT Pharma SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Mar 30, 2026
- -1.65
- 52.40%
- -793.80%
- 107.1%
About MAAT
- Founded
- 2014
- Employees
- 65
- CEO
- WebsiteView website
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
